Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Københavns Universitets forskningsportal Forside
Hjælp og OSS
Dansk
English
Forside
Profiler
Publikation
Forskningsenheder
Presse/medier
Aktiviteter
Priser
???studenttheses???
Forskningsdatasæt
Søg efter ekspertise, navn eller tilknytning
Safety concerns and risk management of multiple sclerosis therapies
P. Soelberg Sorensen
*
*
Corresponding author af dette arbejde
Institut for Klinisk Medicin
39
Citationer (Scopus)
Oversigt
Fingeraftryk
Fingeraftryk
Dyk ned i forskningsemnerne om 'Safety concerns and risk management of multiple sclerosis therapies'. Sammen danner de et unikt fingeraftryk.
Sorter
Vægt
Alfabetisk
Keyphrases
Risk Management
100%
Relapsing-remitting multiple Sclerosis
100%
Safety Risk
100%
Safety Concerns
100%
Life-threatening
100%
Multiple Sclerosis Treatment
100%
Current Treatment
50%
Initial Treatment
50%
Disease Activity
50%
Alemtuzumab
50%
Daclizumab
50%
Intramuscular Injection
50%
Natalizumab
50%
Glatiramer Acetate
50%
Fingolimod
50%
Patient Selection
50%
Tumefactive multiple Sclerosis
50%
Effective Compounds
50%
Benefit-risk Assessment
50%
Patient Demand
50%
Adverse Effects
50%
Risk-benefit Ratio
50%
Subcutaneous Injection
50%
Treatment Algorithm
50%
Interferon-α (IFN-α)
50%
Severe Adverse Effects
50%
Effective Therapy
50%
Highly Effective
50%
Serious Adverse Effects
50%
Neurologist
50%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Teriflunomide
50%
Fumaric Acid Dimethyl Ester
50%
Subcutaneous Injection
25%
Intramuscular Injection
25%
Glatiramer
25%
Natalizumab
25%
Interferon
25%
Daclizumab
25%
Alemtuzumab
25%
Side Effect
25%
Disease Activity
25%
Risk Evaluation
25%
Fingolimod
25%
Neuroscience
Teriflunomide
66%
Alemtuzumab
33%
Daclizumab
33%